Positive Phase 2b ICONA interim results for icosabutate in NASH patients
Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients...
View ArticleClik here to view.
Icosabutate latest phase 2b interim data show significant decreases in NASH...
Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severityResults presented at the AASLD Liver Meeting...
View ArticleNorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance...
Financing co-led by Ysios Capital and Forbion Growth Amsterdam, The Netherlands, 17 December 2021 – NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies...
View ArticleNorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the...
Pre-clinical studies demonstrated beneficial effects of SEFA-6179 in preventing the development of parenteral nutrition-induced cholestasis and liver injury associated with intestinal failure...
View ArticleClik here to view.
NorthSea Therapeutics appoints Morris J. Birnbaum to the Board
Former Pfizer Internal Medicine CSO joins the Boardas an independent board member Amsterdam, The Netherlands, 21 December 2022 – NorthSea Therapeutics B.V. (‘NST’), a biotech company developing...
View ArticleNorthSea Therapeutics provides clinical update reflecting progress across...
– NorthSea Therapeutics now has three phase II clinical stage assets in development based on its SEFA platform – Top line results of Phase 2b ICONA trial with lead programme icosabutate for NASH...
View ArticleNorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for...
– RPD designation underscores critical need for novel therapies to address IFALD Amsterdam, The Netherlands, October 17 — NorthSea Therapeutics B.V. (NST), a biotech company developing novel and...
View ArticleClik here to view.
NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker...
Study results identify NASH patients with Type 2 Diabetes as the key target population for Icosabutate therapy − ICONA study assessed the safety, tolerability and efficacy of Icosabutate, a novel,...
View ArticleNorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in...
Phase 2a study evaluating the safety, tolerability, PK, and PD of Orziloben in IFALD The study will enrol up to 36 adult subjects at multiple sites in North America Study strengthens NST’s position as...
View ArticleNorthSea Therapeutics statement on the passing of Dr. Stephen Harrison
Amsterdam, The Netherlands, 26 April 2024 – The NorthSea team is deeply saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family and loved ones....
View Article